[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tolerance\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tolerance":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,44,84,112,142,166,192,214,238],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100340034","phase-1-study-of-combined-kidney-and-blood-stem-cell-transplant-from-a-brother-or-sister-donor-100340034",false,"NCT03707262","Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister Donor","Donor Chimerism and Graft Survival Following Combined HLA-Identical Sibling Living Donor Kidney and Hematopoietic Stem Cell Transplantation Utilizing a Conditioning Regimen of Total Lymphoid Irradiation and Rabbit Anti-Thymocyte Globulin","Recipient Inclusion Criteria:\n\n1. Males and females ages 18 years and older receiving living donor kidney transplant from an HLA-identical sibling at UCLA Medical Center.\n2. Agrees to participate in the study and is able to give informed consent.\n3. Resides or is willing to stay within 3 hours distance from UCLA Medical Center by ground transportation for the first three to six months of the trial at the physician's discretion.\n4. Meets institutional criteria for kidney and HSPC transplant.\n5. No known contraindication to administration of rATG or radiation.\n6. If patient is a female of reproductive potential (i.e., no documented absence of ovaries or uterus, history of tubal ligation, or post-menopausal status) patient must be confirmed not pregnant by a serum or urine pregnancy test) and must agree to practice a reliable form of contraception including hormonal treatments, barrier methods or intrauterine device for at least 12 months post-transplant. Karnofsky Performance Score ≥ 70.\n7. Adequate cardiac function defined as left ventricular ejection fraction (LVEF) ≥ 40% by MUGA (Multi Gated Acquisition) scan or echocardiogram.\n8. Adequate pulmonary function defined as FVC and DLCO of greater than or equal to 50% of predicted.\n9. Adequate liver function defined as total bilirubin ≤ 1.5 times the upper limit of normal and AST\u002FALT ≤ 2.0 times the upper limit of normal.\n10. Adequate social support based on evaluation by the UCLA renal transplant team licensed clinical social worker.\n\nRecipient Exclusion Criteria:\n\n1. Donor is identical twin.\n2. ABO incompatibility with donor.\n3. Previous solid organ transplant\n4. Multi-organ transplantation\n5. Previous treatment with rATG or a known allergy to rabbit proteins\n6. History of active malignancy within the past 5 years with the exception of non-melanomatous skin cancer.\n\n   a. History of another primary malignancy except for: i. Malignancy treated with curative intent and with no known active disease \\>2 years before the first dose of study treatment and of low potential risk for recurrence ii. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease iii. Very low risk and low risk cancer adequately treated or on active surveillance b. Adequately treated carcinoma in situ without evidence of disease (e.g., cervical cancer in situ, and DCIS)\n7. Pregnant (confirmed by urine or serum pregnancy test) or lactating.\n8. Leukopenia (with a white blood cell count \\\u003C 3,000\u002F µL) or thrombocytopenia (with a platelet count \\\u003C 100,000\u002F µL).\n9. Active bacterial, fungal, mycobacterial or viral infection (including active hepatitis B and\u002For C).\n10. Positive HLA DSA\n11. Seropositivity for HIV 1, HIV 2, HTLVI, HTLV II\n12. Active West Nile Virus infection\n13. Renal disease with high risk of recurrence (i.e., focal segmental glomerulosclerosis).\n14. Advanced hepatic fibrosis or cirrhosis secondary to hepatitis B and\u002For C diagnosis.\n15. Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia; active extra-renal autoimmune disease requiring immunosuppression.\n16. Active extra-renal autoimmune disease requiring immunosuppression.\n17. Neuropsychiatric illness that precludes the ability to give informed consent and\u002For places the patient as high risk for non-compliance with the safety monitoring requirements of the study.\n18. May not have received other immunosuppressive medications, including but not limited to alemtuzumab, belatacept, sirlolimus, everolimus, azathioprine, basiliximab, and eculizumab within six months of the study treatment. Use of corticosteroids prescribed for a time-limited indication (\\\u003C\u002F= 4 weeks) and stopped at least 4 weeks before the kidney transplant is acceptable.\n19. May not have received immunotherapy drugs such as immune checkpoint inhibitors (e.g. pembrolizumab, nivolumab, and ipilimumab), tumor necrosis factor inhibitors, rituximab, and interleukin-2 within six months of the study treatment.\n20. Current or active abuse of alcohol and\u002For drugs within last 6 months.\n21. BMI 40 or greater.\n\nDonor Inclusion Criteria:\n\n1. HLA-identical sibling on high-resolution HLA typing who is ≥18 years of age.\n2. Meets institutional criteria for living kidney and allogeneic HSPC transplant donation.\n3. Medically fit to tolerate peripheral blood apheresis, including weighing ≥110 pounds, hemoglobin ≥ 11 g\u002FdL, white blood cell count ≥ 3,000\u002FµL, and platelets ≥120,000\u002FµL.\n4. Normal serum chemistry and coagulation studies; or, if abnormal, the differences are not considered clinically significant.\n\nDonor Exclusion Criteria:\n\n1. Recipient is identical twin.\n2. ABO incompatibility with recipient.\n3. Medically unfit to tolerate peripheral blood apheresis (small body size, poor vascular access, not a suitable candidate for placement of a central catheter, etc.).\n4. Pregnant (confirmed by urine or serum pregnancy test) or lactating.\n5. Seropositivity for HIV 1, HIV 2, HTLV I, HTLV II\n6. Active West Nile Virus infection\n7. Active bacterial, fungal, mycobacterial or viral infection (including active hepatitis B and\u002For C)\n8. Psychiatric, addictive, neurological, or other disorder that compromises ability to give true informed consent for participation in this study\n\n   1. History of active malignancy within the past 5 years with the exception:Adequately managed malignancy within the past two years with low risk of recurrence may be acceptable as per clinician discretion\n   2. Adequately managed non-melanoma skin cancer\n   3. Adequately managed carcinoma in situ e.g., cervical cancer in situ, and DCIS\n9. No current or recent use of oral anti-coagulants. (For the purpose of this study, recent is defined as less than 60 days prior to apheresis.). Note: Use of aspirin and non-steroidal anti-inflammatory drugs, for pain and inflammation management purposes, are permitted to enroll in the study, but these drugs must be stopped 14 days prior to apheresis, however subjects who are taking aspirin for its anti-platelet\u002Fanti-thrombotic effect, are excluded.","ALL","18 Years",{"count":19,"type":20},15,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","The purpose of this study is to find out if an investigational treatment will allow kidney transplant recipients to better accept their new kidney and stop immunosuppressive medicines. This study is for kidney transplant recipients who receive a kidney from a sibling donor.\n\nThe investigational treatment is started after kidney transplant. It begins with a regimen of a drug called rabbit anti-thymocyte globulin (rATG) combined with radiation therapy (known as total lymphoid irradiation, or TLI) to the lymph nodes and spleen. This is followed by an infusion of blood stem cells, which will be donated by the same sibling who donated their kidney. Researchers think that this treatment allows immune cells from the donor and recipient to live side by side, a condition referred to as \"mixed chimerism.\" Mixed chimerism may help create a state of \"tolerance\" in kidney transplant recipients in which all immunosuppressive medications can be stopped without rejection of the transplanted kidney.\n\nThis study will test whether (1) the investigational treatment will allow patients to stop immunosuppressive medications after their kidney transplant and (2) if the treatment impacts the rate of kidney rejection and the side effects of immunosuppressive medications.",[27,28,29],"Renal Transplant Rejection","Tolerance","Kidney Transplant",[28,29],"RECRUITING","2026-05-06",{"date":34,"type":35},"2026-05-08","ACTUAL",{"date":37,"type":35},"2019-11-06",{"date":39,"type":20},"2027-05",{"name":41,"class":42},"Jeffrey Veale, MD","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":56,"conditions":57,"keywords":63,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":43},"100479797","self-supporting-nasopharyngeal-airway-ssnpa-treating-upper-airway-obstruction-in-hypotonia-100479797","NCT05527652","Self-Supporting Nasopharyngeal Airway (ssNPA) Treating Upper Airway Obstruction in Hypotonia","Inclusion Criteria:\n\n* Children with Hypotonic Upper Airway Obstruction (HUAO): This includes those who newly diagnosed with obstructive sleep apnea (OSA). These children will undergo overnight polysomnography to determine the presence of OSA (apnea-hypopnea index \\[AHI\\]\\>10 or AHI\\>5 with nocturnal hypoxemia defined as oxygen saturation by pulse oximetry \\[SpO2\\] nadir \\\u003C=75%).\n* All subjects require the presence of at least one symptom of OSA (such as snoring 3 or more nights per week, daytime sleepiness, or hyperactive\u002Finattentive behaviors)\n* Post adenotonsillectomy or those with contraindications to tonsillectomy.\n* Tonsil size 2+ or smaller.\n* Parent\u002Fcaregivers willing and able to provide informed consent and child willing and able to provide assent, where appropriate.\n\nExclusion Criteria:\n\n* AHI ≤10 on polysomnogram (PSG) without hypoxemia or AHI\\\u003C5 with hypoxemia.\n* Any medical reason why Self-Supporting Nasopharyngeal Airway (ssNPA) therapy may not be suitable\n* Active Coronavirus (COVID) 19 infections\n* End-tidal carbon dioxide (ETCO2) or Transcutaneous carbon dioxide (TCO2) values \\>60 mmHg for \\>10% of sleep time on PSG\n* Psychiatric, medical, or social factors likely to invalidate assessments, make adherence with ssNPA highly unlikely or make local follow-up at 8 weeks unfeasible. Some psychiatric conditions may be provoked or exacerbated by OSA, and those most commonly implicated - Attention Deficit\u002FHyperactivity Disorder, Conduct Disorder, and Oppositional Defiant Disorder - will not be exclusions. However, more pervasive conditions such as severe autism will be excluded.\n* Presence of supraglottic airway collapse or more distal airway stenosis or collapse (for example glottic, subglottic stenosis, or concern for distal airway stenosis or malacia)\n* Moderate\u002Fsevere tracheobronchomalacia\n* Need for anticoagulative therapy\n* Bleeding disorder\n* Restrictive thoracic disorders","3 Years","21 Years",{"count":53,"type":20},40,[55],"NA","The researchers are investigating if the Self-Supporting Nasopharyngeal Airway (ssNPA) device can be used in the treatment of obstructive sleep apnea in children with Hypotonic Upper Airway Obstruction (HUAO).",[58,59,60,28,61,62],"Obstructive Sleep Apnea","Hypertonia, Muscle","Nasal Airway Obstruction","Trisomy 21","Down Syndrome",[64,65,59,66,67,68,69,70,71,72,73,74],"Sleep Apnea Syndromes","Sleep Apnea, Obstructive","Apnea","Respiration Disorders","Respiratory Tract Diseases","Sleep Disorders, Intrinsic","Dyssomnias","Sleep Wake Disorders","Nervous System Diseases","Neuromuscular Manifestations","Neurologic Manifestations","2026-03-10",{"date":77,"type":35},"2026-03-12",{"date":79,"type":35},"2022-11-16",{"date":81,"type":20},"2026-12",{"name":83,"class":42},"University of Michigan",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":21,"phases":94,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":43},"100620482","early-phase-1-addition-of-venetoclax-to-combined-hematopoietic-stem-cell-and-kidney-transplantation-100620482","NCT07358195","Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation","Addition of Venetoclax to Combined Reduced Intensity Hematopoietic Stem Cell and Kidney Transplantation for Patients With Chronic Kidney Disease and Hematologic Malignancy","Recipient Inclusion Criteria:\n\n* Patient ages 18-70\n* Underlying hematological malignancy which is deemed as being potentially curable with allogeneic bone marrow or PBSC transplantation by the BMT voting team.\n* Hematological malignancies include, but are not limited to: acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma, multiple myeloma (MM), myelodysplastic syndrome (MDS. Patient should be in a partial (PR) or complete remission (CR) at the time of the transplant.\n* Existence of an HLA-matched or haploidentical relative who passes standard donor evaluations for bone marrow and kidney donation\n* LVEF \\> 40% as measured by echocardiography or MUGA\n* FEV1, FVC, and DLCO \\> 50% of predicted as measured by standard PFTs\n* Total bilirubin \\\u003C 2.0 (unless diagnosis of Gilbert's or hemolysis is made) and AST, ALT, alkaline phosphatase all \\\u003C 5x institutions upper limit of normal\n* ABO compatibility in the host vs. graft direction\n* Men and women of reproductive potential must agree to use a reliable method of birth control during the treatment, and women should do so for a period of 1 year following the transplant.\n* Participants should be on dialysis or have a CrCl ≤ 35 ml\u002Fmin\n* Life expectancy greater than 6 months\n* Recipient ability to understand and provide informed consent\n\nDonor Inclusion Criteria:\n\n* HLA matched or haploidentical relative as defined by 3\u002F6, 4\u002F6, or 5\u002F6 HLA-matched at HLA -A, -B, or -DRB1 who is 18-70 years of age\n* ECOG performance status 0 or 1\n* Excellent health per conventional pre-donor history (medical and psychosocial evaluation)\n\n  • Acceptable laboratory parameters (hematology in normal or near-normal range; liver function \\\u003C 3 times the upper limit of normal and normal creatinine)\n* Compatible ABO blood group\n* Negative donor lymphocyte cross match\n* No positive testing for active viral infection (Hepatitis B, Hepatitis C, HIV)\n* Donor ability to understand and provide informed consent\n* Meets standard institutional criteria for both bone marrow or peripheral blood stem cell (PBSC) and kidney donation\n\nExclusion Criteria:\n\n* Active serious infection\n* Participation in other investigational drug use at the time of enrollment\n* Positivity for active infection with HIV, HCV, or HBV\n* ABO blood group incompatibility in the host-vs-graft direction","70 Years",{"count":93,"type":20},3,[95],"EARLY_PHASE1","The primary objective is to assess the safety of the addition of venetoclax to reduced intensity conditioning for HLA-matched and haploidentical combined HSC and kidney transplantation as measured by stable full donor hematopoiesis and absence of CTCAE grade IV or V toxicity attributable to venetoclax.",[98,99,100,28,101],"Kidney Failure Chronic","Stem Cell Transplant","Stem Cell Transplant Complications","Hematologic Cancer","NOT_YET_RECRUITING","2026-01-13",{"date":105,"type":35},"2026-01-22",{"date":107,"type":20},"2026-07",{"date":109,"type":20},"2029-12",{"name":111,"class":42},"Massachusetts General Hospital",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":21,"phases":123,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":43},"100488792","phase-4-effect-of-erugliflozin-on-liver-fat-liver-fibrosis-and-glycemic-control-in-type-ii-dm-patients-with-nashnafld-100488792","NCT05644717","Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH\u002FNAFLD","Effects of Ertugliflozin on Liver Fat, Liver Fibrosis & Glycemic Control in Subjects With Type 2 Diabetes Mellitus (T2DM) & Non-Alcoholic Fatty Liver Disease \u002FNon-Alcoholic Steatohepatitis","Ertu-NASH","Inclusion Criteria:\n\n* Patient able to provide written informed consent\n* Adult males \\& females between 18 to 65 years\n* SGLT2i and insulin naïve patients\n* BMI \\>23 Kg\u002Fm2\n* HbA1C % ≥ 6.5 to 10\n* Documented hepatic steatosis or fatty liver disease on Ultrasound\n* Patient with Type II Diabetes Mellitus\n\nExclusion Criteria:\n\n* History of use of SGLT 2 inhibitors or Glucagon-like peptide (GLP) 1 agonist or insulin; 3 months prior to enrollment in the study.\n* Pioglitazone use in the past 6 months\n* History of vitamin E use (400mg twice daily) 3 months prior to enrollment in the study.\n* History of anti-obesity medication or weight loss procedure (bariatric surgery) use within 3 months prior to enrollment in the study.\n* History of uncontrolled Endocrine disorder (for example uncontrolled hypothyroidism, or that requires frequent dose adjustment, or Cushing's syndrome)\n* History of liver disease including viral hepatitis, auto-immune hepatitis, liver cirrhosis, hepatocellular carcinoma and\u002For HIV\n* History of recurrent UTIs and mycotic infection.\n* Severely ill patients (who have high grade fever, sepsis or acute infection)\n* Pregnant woman, lactating woman or planning pregnancy during study duration\n* History of Drug-induced liver disease (e.g. amiodarone, valproate, tamoxifen, methotrexate, steroids (including homeopathic medicines).\n* History of active substance abuse (cannabinoid-derived substances like heroin, cocaine, amphetamines) based on history and\u002For laboratory tests\n* Alcohol intake 10 - 30 g\u002Fday (three drinks per day) within the previous year\n* Active substance abuse such as acetaminophen over-use, hashish, tobacco products, heroin, cocaine or amphetamines.\n* Severe hepatic impairment ( AST \\& ALT levels \\> 3 times upper limit normal","65 Years",{"count":122,"type":20},164,[124],"PHASE4","Open-label, prospective, single-arm, multicenter study to determine effects of Ertugliflozin on liver fat, liver fibrosis \\& glycemic control in subjects with Type 2 Diabetes Mellitus (T2DM) with Non-Alcoholic Fatty Liver Disease (NAFLD)\u002FNon-Alcoholic Steatohepatitis (NASH)",[127,128,129,130,131,28],"Liver Fat","Liver Fibrosis","Glycemic Control","Body Weight Changes","Waist Circumference","2025-03-19",{"date":134,"type":35},"2025-03-21",{"date":136,"type":35},"2023-03-01",{"date":138,"type":20},"2025-12-01",{"name":140,"class":141},"Getz Pharma","INDUSTRY",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":149,"sex":16,"minAge":17,"maxAge":150,"enrollmentInfo":151,"targetDuration":4,"studyType":21,"phases":153,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":43},"100530622","early-phase-1-phase-i-study-to-evaluate-kp405-in-healthy-and-parkinsons-disease-patients-100530622","NCT06189170","Phase I Study to Evaluate KP405 in Healthy and Parkinson's Disease Patients","A Phase I, Randomised, Double-Blinded, Placebo-Controlled Study to Evaluate KP405. Part 1: Single Ascending Dosing in Healthy Participants. Part 2: Multiple Ascending Dosing in Healthy Participants and Parkinson's Disease Patients.","Inclusion Criteria:\n\n* Healthy as determined by a responsible physician, based on medical evaluation including medical history, physical examination, concomitant medication, vital signs, 12-lead ECG, cardiac Holter monitoring and clinical laboratory evaluations.\n* Clinical diagnosis of Parkinson's disease meeting United Kingdom Brain Bank criteria.\n\nExclusion Criteria:\n\n* Clinically relevant history of abnormal physical or mental health interfering with the study as determined by medical history and physical examinations obtained during Screening as judged by the Investigator (including \\[but not limited to\\], neurological, psychiatric, endocrine, cardiovascular, respiratory, gastrointestinal, hepatic, or renal disorder), excluding Parkinson's disease.\n* Clinically significant, as judged by the Investigator, neurologic disorder (other than Parkinson's disease) including history of stroke or transient ischaemic attack within 12 months of Screening, cognitive impairment, seizure within 5 years of Screening or head trauma with loss of consciousness within 6 months of Screening.",true,"80 Years",{"count":152,"type":20},88,[95],"This study will explore the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of KP405 as a potential new treatment for Parkinson's disease.",[156,28],"Safety Issues","2025-03-04",{"date":159,"type":35},"2025-03-07",{"date":161,"type":35},"2024-08-01",{"date":163,"type":20},"2026-03-31",{"name":165,"class":141},"Kariya Pharmaceuticals",{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":21,"phases":175,"briefSummary":176,"conditions":177,"keywords":180,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":43},"100578731","risk-factors-for-poor-tolerance-of-ureteral-double-j-stent-100578731","NCT06815107","Risk Factors for Poor Tolerance of Ureteral Double-J Stent","ToleJJ","Inclusion Criteria:\n\n* patient over 18 years old\n* patient who need Ureteral Double-J Stenting\n\nExclusion Criteria:\n\n* patient under 18 years old,\n* Iterative change,\n* understanding disorder,\n* inability to answer the questionnaire,\n* refusal of the patient,\n* long-term Ureteral Double-J Stenting (more than 6 month),\n* active cancer.",{"count":174,"type":20},200,[55],"The placement of a Ureteral Double-J Stent as an emergency treatment or preparation for endoscopy after Colic nephritis is very frequent. It is often poorly supported, most often by young patients. A rich symptomatology is related to the probe responsible for a limitation of activities that can have a strong socio-economic impact. The objective of this study is the identification of the predictive factors of poor tolerance.",[28,178,179],"Ureteral Double-J Stent","Urinary Symptoms",[178,181,182],"tolerance","urinary symptom","2025-02-04",{"date":185,"type":35},"2025-02-07",{"date":187,"type":35},"2020-04-15",{"date":189,"type":20},"2026-04",{"name":191,"class":42},"Centre Hospitalier Universitaire, Amiens",{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":149,"sex":199,"minAge":17,"maxAge":120,"enrollmentInfo":200,"targetDuration":4,"studyType":21,"phases":202,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":4},"100571635","phase-1-study-to-evaluate-lph-5-in-healthy-subjects-100571635","NCT06722820","Study to Evaluate LPH-5 in Healthy Subjects","Phase I, First-in-man, Randomised, Placebo-controlled, Single Dose Escalation Study to Investigate the Effects of LPH-5 on Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Parameters in Healthy Participants","Inclusion Criteria:\n\n* Healthy as determined by a responsible physician, based on medical evaluation including medical history, physical examination, concomitant medication, vital signs, 12-lead ECG, and clinical laboratory evaluations.\n\nExclusion Criteria:\n\n* Any condition or disease detected during the medical interview\u002Fphysical examination that could relapse during or immediately after the study, or would render the participant unsuitable for the study, place the participant at undue risk, or interfere with the ability of the participant to complete the clinical study, as determined by the Investigator.\n* Have a history of and\u002For current clinically significant determined by the Investigator\n* Consumes cannabis or cannabis-derived compounds more than 3 times per month or has substantial changes in cannabis consumption in the 21 days prior to screening.","MALE",{"count":201,"type":20},48,[23],"This study will explore the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of LPH-5.",[156,28],"2024-12-03",{"date":207,"type":35},"2024-12-09",{"date":209,"type":20},"2025-04-30",{"date":211,"type":20},"2025-12-31",{"name":213,"class":141},"Lophora",{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":149,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":21,"phases":223,"briefSummary":224,"conditions":225,"keywords":228,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":43},"100358882","intranasal-capsaicinoid-spray-100358882","NCT03952845","Intranasal Capsaicinoid Spray","Tolerability of Intranasal Capsaicinoid Spray","Inclusion Criteria:\n\n* Healthy adults\n* American Association of Anesthesiology Class 1,\"A normal, healthy patient\" only\n\nExclusion Criteria:\n\n* Age less than 18 years\n* Pregnancy\n* Previous nasal or paranasal sinus surgery or radiation\n* Allergies to capsaicinoids or capsaicinoid containing products (any combination of sweet peppers, or hot peppers).",{"count":222,"type":20},30,[55],"Rhinitis is inflammation of the inside of the nose. Symptoms of rhinitis include itchiness, sneezing, and a \"runny\" nose (rhinorrhea). There are many different causes for rhinitis, including allergies, age, different irritants in the air, overacting nervous system, and others.\n\nMany current treatments for rhinitis are not helpful or are unable to be used for long periods of time. Capsaicin (\"Kap-Sey-Uh-Sin\") is a natural product that is found in many spicy foods, including hot peppers. This natural product has been used as a lotion to prevent pain, and scientists have found that it may reduce the symptoms of rhinitis when used as a spray in the nose.\n\nHowever, capsaicin is known to cause a burning sensation. This study is needed so we can figure out what doses of capsaicin cause this burning sensation, and to what level these doses cause discomfort. Capsaicin can also cause a small degree of tearing from the eyes when used as a spray in the nose, and can also cause the nose to become \"runny\" (rhinorrhea).\n\nWhen the safest dose of capsaicin spray is found, that dose can be used to treat people with rhinitis that is not getting better from standard treatments.",[28,226,227],"Capsaicin","Rhinitis",[226,227],"2024-08-19",{"date":231,"type":35},"2024-08-21",{"date":233,"type":20},"2025-08-01",{"date":235,"type":20},"2030-12-01",{"name":237,"class":42},"Nova Scotia Health Authority",{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":4,"eligibilityCriteria":244,"healthyVolunteers":149,"sex":16,"minAge":17,"maxAge":245,"enrollmentInfo":246,"targetDuration":4,"studyType":21,"phases":248,"briefSummary":249,"conditions":250,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":43},"100550071","safety-and-tolerability-of-2-dietary-supplement-beverages-designed-to-maintain-healthy-blood-pressure-100550071","NCT06442293","Safety and Tolerability of 2 Dietary Supplement Beverages Designed to Maintain Healthy Blood Pressure.","An Evaluation of the Safety and Tolerability of 2 Dietary Supplement Beverages Designed to Maintain Normal Blood Pressure in Normal, Healthy Individuals.","Inclusion Criteria:\n\n* You are male or female between the ages of 18 and 50 (inclusive)\n* You are in generally good health and taking no medications known to treat or affect blood pressure (e.g., angiotensin converting enzyme (ACE) inhibitors, calcium channel blockers, diuretics)\n* You have a Body Mass Index of 18.5 to 30.0\n* You have a resting blood pressure of systolic blood pressure (SBP) of 90 - 120 mm Hg and a diastolic blood pressure (DBP) 60 - 80 mm Hg\n* You are comfortable reading and speaking in English\n* You are fully able and willing to comply with the requirements of the study\n* You are fully able and willing to keep scheduled appointments\n* You have no known food allergies or intolerances\n* Female individuals will be asked to complete a pregnancy screening test.\n\nExclusion Criteria:\n\n* You are pregnant, attempting to become pregnant, or are currently lactating\n* You currently use prescription or over-the-counter medications that may interfere with absorption of the test supplement or confound results (e.g., thiazide and loop diuretics for hypertension, corticosteroids)\n* You have clinically important gastrointestinal, renal, hepatic, cardiac, pulmonary, pancreatic, neurologic or biliary disorders or conditions. Individuals with type 1 or type 2 diabetes will be excluded from the study\n* You have illnesses or other medical conditions that will prevent or interfere with giving an informed consent, or with participation in the study.\n* You have scheduling difficulties or lack of transportation that will prevent or interfere with their ability to attend all the necessary study visits.\n* You have participated as a subject in any other clinical study within 30 days of the screening visit.\n* You have a history of alcohol abuse or other substance abuse within the previous 2 years.\n* You are currently using tobacco products including chewing tobacco and cigarettes.","50 Years",{"count":247,"type":20},18,[55],"This study is designed to evaluate the safety and tolerability of two distinct dietary supplement beverage formulations designed to maintain normal blood pressure. In this study, safety and tolerability will be assessed among otherwise healthy, normotensive individuals.",[156,28],"2024-06-02",{"date":253,"type":35},"2024-06-04",{"date":255,"type":20},"2024-07-01",{"date":257,"type":20},"2024-08-15",{"name":259,"class":141},"USANA Health Sciences"]